SlideShare a Scribd company logo
20.06.2018
1
Sexually transmitted diseases
Tevfik Yoldemir MD BSc MA
www.yoldemir.com
Chancroid
• The combination of a painful genital ulcer and tender
suppurative inguinal adenopathy suggests the diagnosis of
chancroid
1) the patient has one or more painful genital ulcers;
2) the clinical presentation, appearance of genital ulcers and, if
present, regional lymphadenopathy are typical for chancroid;
3) the patient has no evidence of T. pallidum infection by
darkfield examination of ulcer exudate or by a serologic test for
syphilis performed at least 7 days after onset of ulcers; and
4) an HSV PCR test or HSV culture performed on the ulcer
exudate is negative
Chancroid
Recommended Regimens
Azithromycin 1 g orally in a single dose
OR
Ceftriaxone 250 mg IM in a single dose
OR
Ciprofloxacin 500 mg orally twice a day for 3 days
OR
Erythromycin base 500 mg orally three times a day for 7 days
Herpes
• Painful multiple vesicular or ulcerative lesions typically associated
with HSV are absent in many infected persons.
• Cell culture and PCR are the preferred HSV tests for persons who
seek medical treatment for genital ulcers or other mucocutaneous
lesions.
Recommended Regimens
Acyclovir 400 mg orally three times a day for 7–10 days
OR
Acyclovir 200 mg orally five times a day for 7–10 days
OR
Valacyclovir 1 g orally twice a day for 7–10 days
OR
Famciclovir 250 mg orally three times a day for 7–10 days
Suppressivetherapyfor recurrentgenital
herpes
Recommended Regimens
Acyclovir 400 mg orally twice a day
OR
Valacyclovir 500 mg orally once a day*
OR
Valacyclovir 1 g orally once a day
OR
Famiciclovir 250 mg orally twice a day
Episodictherapyforrecurrentgenital herpes
Recommended Regimens
Acyclovir 400 mg orally three times a day for 5 days
OR
Acyclovir 800 mg orally twice a day for 5 days
OR
Acyclovir 800 mg orally three times a day for 2 days
OR
Valacyclovir 500 mg orally twice a day for 3 days
OR
Valacyclovir 1 g orally once a day for 5 days
OR
Famciclovir 125 mg orally twice daily for 5 days
OR
Famciclovir 1 gram orally twice daily for 1 day
OR
Famciclovir 500 mg once, followed by 250 mg twice daily for 2 days
20.06.2018
2
Suppressivetherapyof a pregnantwomen
Recommended regimenfor suppressive therapy of pregnant
women with recurrent genital herpes *
Acyclovir 400 mg orally three times a day
OR
Valacyclovir 500 mg orally twice a day
* Treatment recommended starting at 36 weeks of gestation
GranulomaInguinale(Donovanosis)
• Painless, slowly progressive ulcerative lesions on the genitals or
perineum without regional lymphadenopathy; subcutaneous
granulomas (pseudobuboes) also might occur.
• The lesions are highly vascular (i.e., beefy red appearance) and
bleed.
• Extragenitalinfection can occur with extension of infection to
the pelvis, or it can disseminate to intra-abdominal organs,
bones, or the mouth.
• The lesions also can develop secondary bacterial infection and
can coexist with other sexually transmitted pathogens.
• Diagnosis requires visualization of dark-staining Donovan
bodies on tissue crush preparation or biopsy.
RecommendedRegimen
Azithromycin 1 g orally once per week or 500 mg daily for at least 3
weeks and until all lesions have completely healed
Alternative Regimens
Doxycycline 100 mg orally twice a day for at least 3 weeks and until all
lesions have completely healed
OR
Ciprofloxacin 750 mg orally twice a day for at least 3 weeks and until all
lesions have completely healed
OR
Erythromycin base 500 mg orally four times a day for at least 3 weeks
and until all lesions have completely healed
OR
Trimethoprim-sulfamethoxazole one double-strength (160 mg/800 mg)
tablet orally twice a day for at least 3 weeks and until all lesions have
completely healed
LymphogranulomaVenereum
• tender inguinal and/or femoral lymphadenopathy that is
typicallyunilateral.
• A self-limited genital ulcer or papule sometimes occurs at the
site of inculation.
• Genital lesions, rectal specimens, and lymph node specimens
(i.e., lesion swab or bubo aspirate) can be tested for C.
trachomatis by culture, direct immunofluorescence, or nucleic
acid detection
• Chlamydia serology (complement fixation titers ≥1:64 or
microimmunofluorescencetiters >1:256) might support the
diagnosis of LGV
Recommended Regimen
Doxycycline 100 mg orally twice a day for 21 days
Alternative Regimen
Erythromycin base 500 mg orally four times a day for 21 days
Syphilis
• Persons who have syphilis might seek treatment for signs or
symptoms of primary syphilis infection (i.e., ulcers or chancre
at the infection site),
• secondary syphilis (i.e., manifestations that include, but are not
limited to, skin rash, mucocutaneous lesions, and
lymphadenopathy), or
• tertiary syphilis (i.e., cardiac, gummatous lesions, tabes
dorsalis, and general paresis).
• Darkfield examinations and tests to detect T. pallidum directly
from lesion exudate or tissue are the definitive methods for
diagnosing early syphilis.
20.06.2018
3
Recommended Regimen for Adults*
Benzathine penicillin G 2.4 million units IM in a single dose
Recommended Regimens for Adults*
Early Latent Syphilis
Benzathine penicillin G 2.4 million units IM in a single dose
Late Latent Syphilis or Latent Syphilis of Unknown Duration
Benzathine penicillin G 7.2 million units total, administered as 3
doses of 2.4 million units IM each at 1-week intervals
Recommended Regimen for Infants and Children
Benzathine penicillin G 50,000 units/kg IM, up to the adult dose of
2.4 million units in a single dose
Recommended Regimens for Infants and Children
Early Latent Syphilis
Benzathine penicillin G 50,000 units/kg IM, up to the adult dose of
2.4 million units in a single dose
Late Latent Syphilis
Benzathine penicillin G 50,000 units/kg IM, up to the adult dose of
2.4 million units, administered as 3 doses at 1-week intervals (total
150,000 units/kg up to the adult total dose of 7.2 million units)
ChlamydialInfections
• C. trachomatis urogenital infection can be diagnosed in women
by testing first-catch urine or collecting swab specimens from
the endocervix or vagina.
• Diagnosis of C. trachomatis urethral infection in men can be
made by testing a urethral swab or first-catch urine specimen.
Recommended Regimens
Azithromycin 1 g orally in a single dose
OR
Doxycycline 100 mg orally twice a day for 7 days
Alternative Regimens
Erythromycin base 500 mg orally four times a day for 7 days
OR
Erythromycin ethylsuccinate 800 mg orally four times a day for
7 days
OR
Levofloxacin 500 mg orally once daily for 7 days
OR
Ofloxacin 300 mg orally twice a day for 7 days
Pregnancy
Recommended Regimens
Azithromycin 1 g orally in a single dose
Alternative Regimens
Amoxicillin 500 mg orally three times a day for 7 days
OR
Erythromycin base 500 mg orally four times a day for 7 days
OR
Erythromycin base 250 mg orally four times a day for 14 days
OR
Erythromycin ethylsuccinate 800 mg orally four times a day for 7 days
OR
Erythromycin ethylsuccinate 400 mg orally four times a day for 14 days
GonococcalInfections
• Culture and NAAT are available for the detection of
genitourinary infection with N. gonorrhoeae (394); culture
requires endocervical (women) or urethral (men) swab
specimens
• Detection of infection using Gram stain of endocervical,
pharyngeal, and rectal specimens also is insufficient and is not
recommended. MB/GV stain of urethral secretions is an
alternative point-of-care diagnostic test with performance
characteristics similar to Gram stain.
• Presumed gonococcal infection is established by documenting
the presence of WBC containing intracellular purple diplococci
in MB/GV smears.
20.06.2018
4
Recommended Regimen
Ceftriaxone 250 mg IM in a single dose
PLUS
Azithromycin 1g orally in a single dose
Alternative Regimens
If ceftriaxone is not available:
Cefixime 400 mg orally in a single dose
PLUS
Azithromycin 1 g orally in a single dose
BacterialVaginosis
• anaerobic bacteria (e.g., Prevotella sp. and Mobiluncus sp.), G.
vaginalis, Ureaplasma, Mycoplasma, and numerous fastidious
or uncultivated anaerobes.
• Gram stain (considered the gold standard laboratory method
for diagnosing BV) is used to determine the relative
concentration of lactobacilli (i.e., long Gram-positive rods),
Gram-negative and Gram-variable rods and cocci (i.e., G.
vaginalis, Prevotella, Porphyromonas, and peptostreptococci),
and curved Gram-negative rods (i.e., Mobiluncus) characteristic
of BV.
Clinical criteria require three of the following symptoms or signs:
• homogeneous, thin, white discharge that smoothly coats the
vaginal walls;
• clue cells (e.g., vaginal epithelial cells studded with adherent
coccoobacilli) on microscopic examination;
• pH of vaginal fluid >4.5; or
• a fishy odor of vaginal discharge before or after addition of 10%
KOH (i.e., the whiff test).
RecommendedRegimens
Metronidazole 500 mg orally twice a day for 7 days
OR
Metronidazole gel 0.75%, one full applicator (5 g) intravaginally, once a day
for 5 days
OR
Clindamycin cream 2%, one full applicator (5 g) intravaginally at bedtime for
7 days
Alternative Regimens
Tinidazole 2 g orally once daily for 2 days
OR
Tinidazole 1 g orally once daily for 5 days
OR
Clindamycin 300 mg orally twice daily for 7 days
OR
Clindamycin ovules 100 mg intravaginally once at bedtime for 3 days*
Trichomoniasis
Recommended Regimen
Metronidazole 2 g orally in a single dose
OR
Tinidazole 2 g orally in a single dose
Alternative Regimen
Metronidazole 500 mg orally twice a day for 7 days
VulvovaginalCandidiasis
• Use of 10% KOH in wet preparations improves the visualization
of yeast and mycelia by disrupting cellular material that might
obscure the yeast or pseudohyphae.
• Examination of a wet mount with KOH preparation should be
performed for all women with symptoms or signs of VVC
20.06.2018
5
VulvovaginalCandidiasis
Recommended Regimens
Over-the-Counter Intravaginal Agents:
Clotrimazole 1% cream 5 g intravaginally daily for 7–14 days
OR
Clotrimazole 2% cream 5 g intravaginally daily for 3 days
OR
Miconazole 2% cream 5 g intravaginally daily for 7 days
OR
Miconazole 4% cream 5 g intravaginally daily for 3 days
OR
Miconazole 100 mg vaginal suppository, one suppository daily for 7 da
OR
Miconazole 200 mg vaginal suppository, one suppository for 3 days
OR
Miconazole 1,200 mg vaginal suppository, one suppository for 1 day
OR
Tioconazole 6.5% ointment 5 g intravaginally in a single application
• Prescription Intravaginal Agents:
• Butoconazole 2% cream (single dose bioadhesive product), 5 g
intravaginally in a single application
• OR
• Terconazole 0.4% cream 5 g intravaginally daily for 7 days
• OR
• Terconazole 0.8% cream 5 g intravaginally daily for 3 days
• OR
• Terconazole 80 mg vaginal suppository, one suppository daily for 3
days
• Oral Agent:
• Fluconazole 150 mg orally in a single dose
Pelvic InflammatoryDisease
If one or more of the following minimum clinical criteria are present on
pelvic examination:
• cervical motion tenderness or uterine tenderness or adnexal
tenderness.
One or more of the following additional criteria can be used to
enhance the specificity of the minimum clinical criteria and support a
diagnosis of PID:
• oral temperature >101°F (>38.3°C);
• abnormal cervical mucopurulent discharge or cervical friability;
• presence of abundant numbers of WBC on saline microscopy of
vaginal fluid;
• elevated erythrocyte sedimentation rate;
• elevated C-reactive protein; and
• laboratory documentation of cervical infection with N. gonorrhoeae
or C. trachomatis.
DifferentialDiagnosisfor PID
• Endometriosis
• Appendicitis & other gastro conditions
• Appendicitis is unilateral and right sided
• PID is bilateral
• Ectopic pregnancy
• Always do a pregnancy test
• Urinary tract infection or stone
• “Ovarian cysts”
• Lower genital tract infection
PID Sequelae
• Chronic Pelvic Pain (15-20 %)
• Ectopic pregnancy (6-10 fold ↑Risk)
• At least 50% of tubal pregnancies have histology
of PID
• Infertility (Tubal)
• 10 – 15% after one episode
• 20% ~ 2 episode
• >40% ~ 3 episodes
• Recurrence of acute PID at least 25%
• Male genital disease in 25%
20.06.2018
6
RecommendedParenteralRegimens
Cefotetan 2 g IV every 12 hours
PLUS
Doxycycline 100 mg orally or IV every 12 hours
OR
Cefoxitin 2 g IV every 6 hours
PLUS
Doxycycline 100 mg orally or IV every 12 hours
OR
Clindamycin 900 mg IV every 8 hours
PLUS
Gentamicin loading dose IV or IM (2 mg/kg), followed by a
maintenance dose (1.5 mg/kg) every 8 hours. Single daily dosing
(3–5 mg/kg) can be substituted.
AlternativeParenteralRegimen
Ampicillin/Sulbactam 3 g IV every 6 hours
PLUS
Doxycycline 100 mg orally or IV every 12 hours
RecommendedIntramuscular/OralRegimens
Ceftriaxone 250 mg IM in a single dose
PLUS
Doxycycline 100 mg orally twice a day for 14 days
WITH* or WITHOUT
Metronidazole 500 mg orally twice a day for 14 days
OR
Cefoxitin 2 g IM in a single dose and Probenecid, 1 g orally administered
concurrently in a single dose
PLUS
Doxycycline 100 mg orally twice a day for 14 days
WITH or WITHOUT
Metronidazole 500 mg orally twice a day for 14 days
OR
Other parenteral third-generation cephalosporin (e.g., ceftizoxime or cefotaxime)
PLUS
Doxycycline 100 mg orally twice a day for 14 days
WITH* or WITHOUT
Metronidazole 500 mg orally twice a day for 14 days
RecommendedRegimensfor External
AnogenitalWarts
(i.e., penis, groin, scrotum, vulva, perineum, external anus, and perianus*)
Patient-Applied:
Imiquimod 3.75% or 5% cream†
OR
Podofilox 0.5% solution or gel
OR
Sinecatechins 15% ointment†
Provider–Administered:
Cryotherapy with liquid nitrogen or cryoprobe
OR
Surgical removal either by tangential scissor excision, tangential shave
excision, curettage, laser, or electrosurgery
OR
Trichloroacetic acid (TCA) or bichloroacetic acid (BCA) 80%–90% solution
RecommendedRegimensfor Vaginal Warts
Cryotherapy with liquid nitrogen. The use of a cryoprobe in the
vagina is not recommended because of the risk for vaginal
perforation and fistula formation.
OR
Surgical removal
OR
TCA or BCA 80%–90% solution
RecommendedRegimensfor CervicalWarts
Cryotherapy with liquid nitrogen
OR
Surgical removal
OR
TCA or BCA 80%–90% solution
Management of cervical warts should include consultation with a
specialist.
For women who have exophytic cervical warts, a biopsy
evaluation to exclude high-grade SIL must be performed before
treatment is initiated
20.06.2018
7
Q & A
www.slideshare.net/dryoldemir
tevfik.yoldemir@marmara.edu.tr

More Related Content

What's hot

Cipromega training
Cipromega trainingCipromega training
Cipromega training
Mohamed Salah Rashwan
 
Bacterial Vaginosis
Bacterial VaginosisBacterial Vaginosis
Bacterial Vaginosis
fitango
 
Prevention of infection-Related Preterm Birth
Prevention of  infection-Related Preterm Birth Prevention of  infection-Related Preterm Birth
Prevention of infection-Related Preterm Birth
Aboubakr Elnashar
 
Recurrent vulvovaginal Candidiasis
Recurrent vulvovaginal CandidiasisRecurrent vulvovaginal Candidiasis
Recurrent vulvovaginal Candidiasis
Aboubakr Elnashar
 
Emergency ultrasonography in 2nd 3rd timester
Emergency ultrasonography in 2nd 3rd timesterEmergency ultrasonography in 2nd 3rd timester
Emergency ultrasonography in 2nd 3rd timester
Aboubakr Elnashar
 
2.04.03 bovine brucell
2.04.03 bovine brucell2.04.03 bovine brucell
2.04.03 bovine brucell
Samianajm
 
Fungal Vulvovaginal Infection
Fungal Vulvovaginal InfectionFungal Vulvovaginal Infection
Fungal Vulvovaginal Infection
Mamdouh Sabry
 
Antibiotics in Egyptian pharmacies
Antibiotics in Egyptian pharmaciesAntibiotics in Egyptian pharmacies
Antibiotics in Egyptian pharmacies
Ahmed Gamal Afify
 
Current evidence for management of Refractory Endometrium
Current evidence for management of Refractory Endometrium Current evidence for management of Refractory Endometrium
Current evidence for management of Refractory Endometrium
Aboubakr Elnashar
 
Gynae/ Obstetrics & Antibiotics
Gynae/ Obstetrics & AntibioticsGynae/ Obstetrics & Antibiotics
Gynae/ Obstetrics & Antibiotics
Asad Kamran
 
cephalosporin
cephalosporincephalosporin
cephalosporin
Dam Hassan
 
Cephalosporins
CephalosporinsCephalosporins
Cephalosporins
Afiqah Ariffin
 
Bacterial vaginosis diagnosis
Bacterial vaginosis diagnosisBacterial vaginosis diagnosis
Bacterial vaginosis diagnosis
Aboubakr Elnashar
 
Cephalosporin
CephalosporinCephalosporin
Cephalosporin
faseeha94
 
Pharmacology of Cephalosporins
Pharmacology of CephalosporinsPharmacology of Cephalosporins
Pharmacology of Cephalosporins
ANUSHA SHAJI
 
Medical termination of pregnancy
Medical termination of pregnancyMedical termination of pregnancy
Medical termination of pregnancy
DK Ya'v
 
Cephalosporins
CephalosporinsCephalosporins
Cephalosporins
osamaDR
 
Reurrent Miscarriage
Reurrent MiscarriageReurrent Miscarriage
Reurrent Miscarriage
Aboubakr Elnashar
 

What's hot (18)

Cipromega training
Cipromega trainingCipromega training
Cipromega training
 
Bacterial Vaginosis
Bacterial VaginosisBacterial Vaginosis
Bacterial Vaginosis
 
Prevention of infection-Related Preterm Birth
Prevention of  infection-Related Preterm Birth Prevention of  infection-Related Preterm Birth
Prevention of infection-Related Preterm Birth
 
Recurrent vulvovaginal Candidiasis
Recurrent vulvovaginal CandidiasisRecurrent vulvovaginal Candidiasis
Recurrent vulvovaginal Candidiasis
 
Emergency ultrasonography in 2nd 3rd timester
Emergency ultrasonography in 2nd 3rd timesterEmergency ultrasonography in 2nd 3rd timester
Emergency ultrasonography in 2nd 3rd timester
 
2.04.03 bovine brucell
2.04.03 bovine brucell2.04.03 bovine brucell
2.04.03 bovine brucell
 
Fungal Vulvovaginal Infection
Fungal Vulvovaginal InfectionFungal Vulvovaginal Infection
Fungal Vulvovaginal Infection
 
Antibiotics in Egyptian pharmacies
Antibiotics in Egyptian pharmaciesAntibiotics in Egyptian pharmacies
Antibiotics in Egyptian pharmacies
 
Current evidence for management of Refractory Endometrium
Current evidence for management of Refractory Endometrium Current evidence for management of Refractory Endometrium
Current evidence for management of Refractory Endometrium
 
Gynae/ Obstetrics & Antibiotics
Gynae/ Obstetrics & AntibioticsGynae/ Obstetrics & Antibiotics
Gynae/ Obstetrics & Antibiotics
 
cephalosporin
cephalosporincephalosporin
cephalosporin
 
Cephalosporins
CephalosporinsCephalosporins
Cephalosporins
 
Bacterial vaginosis diagnosis
Bacterial vaginosis diagnosisBacterial vaginosis diagnosis
Bacterial vaginosis diagnosis
 
Cephalosporin
CephalosporinCephalosporin
Cephalosporin
 
Pharmacology of Cephalosporins
Pharmacology of CephalosporinsPharmacology of Cephalosporins
Pharmacology of Cephalosporins
 
Medical termination of pregnancy
Medical termination of pregnancyMedical termination of pregnancy
Medical termination of pregnancy
 
Cephalosporins
CephalosporinsCephalosporins
Cephalosporins
 
Reurrent Miscarriage
Reurrent MiscarriageReurrent Miscarriage
Reurrent Miscarriage
 

Similar to sexually transmitted diseases

2015 guia de cdc para tto de ets y vb
2015 guia de cdc para tto de ets y vb2015 guia de cdc para tto de ets y vb
2015 guia de cdc para tto de ets y vb
Marlyn W. Aguilar Huamán
 
Gynecology genital disease and treatment Dr. Ahmadi.pdf
Gynecology genital disease and treatment Dr. Ahmadi.pdfGynecology genital disease and treatment Dr. Ahmadi.pdf
Gynecology genital disease and treatment Dr. Ahmadi.pdf
TayebehHeidari1
 
DOH National Antibiotic Guidelines 2016 (UTI)
DOH National Antibiotic Guidelines 2016 (UTI)DOH National Antibiotic Guidelines 2016 (UTI)
DOH National Antibiotic Guidelines 2016 (UTI)
Philippine Hospital Infection Contol Nurses Associaton (PHICNA) Inc.
 
Global Medical Cures™ | Sexually Transmitted Diseases (CDC Treatment Guidelines)
Global Medical Cures™ | Sexually Transmitted Diseases (CDC Treatment Guidelines)Global Medical Cures™ | Sexually Transmitted Diseases (CDC Treatment Guidelines)
Global Medical Cures™ | Sexually Transmitted Diseases (CDC Treatment Guidelines)
Global Medical Cures™
 
Chlamydia Infection
Chlamydia Infection Chlamydia Infection
Chlamydia Infection
MahabaToshee
 
Urinary Tract Infection-1.pptx
Urinary Tract Infection-1.pptxUrinary Tract Infection-1.pptx
Urinary Tract Infection-1.pptx
DrHira8
 
2015 pocket-guide
2015 pocket-guide2015 pocket-guide
2015 pocket-guide
Numnim Kanokwan
 
Infections in pregnancy and the puerperium.pptx
Infections in pregnancy and the puerperium.pptxInfections in pregnancy and the puerperium.pptx
Infections in pregnancy and the puerperium.pptx
NkosinathiManana2
 
A B C of URINARY TRACT INFECTION, Dr. Sharda Jain Lifecare Centre
A B C of URINARY TRACT INFECTION, Dr. Sharda Jain Lifecare Centre A B C of URINARY TRACT INFECTION, Dr. Sharda Jain Lifecare Centre
A B C of URINARY TRACT INFECTION, Dr. Sharda Jain Lifecare Centre
Lifecare Centre
 
SINGLE DOSE treatment of URINARY TRACT INFECTION in women, Dr Sharda jain , ...
SINGLE DOSE  treatment of URINARY TRACT INFECTION in women, Dr Sharda jain , ...SINGLE DOSE  treatment of URINARY TRACT INFECTION in women, Dr Sharda jain , ...
SINGLE DOSE treatment of URINARY TRACT INFECTION in women, Dr Sharda jain , ...
Lifecare Centre
 
Std
StdStd
Ciprofloxacin 500mg film coated tablets smpc- taj pharmaceuticals
Ciprofloxacin 500mg film coated tablets smpc- taj pharmaceuticalsCiprofloxacin 500mg film coated tablets smpc- taj pharmaceuticals
Ciprofloxacin 500mg film coated tablets smpc- taj pharmaceuticals
Taj Pharma
 
2_2019_02_23!1ehefguuthutyj0_34_21_PM.pptx
2_2019_02_23!1ehefguuthutyj0_34_21_PM.pptx2_2019_02_23!1ehefguuthutyj0_34_21_PM.pptx
2_2019_02_23!1ehefguuthutyj0_34_21_PM.pptx
Joebest8
 
Brucellosis
BrucellosisBrucellosis
Brucellosis
Ali Najat
 
Malaria by affan ali(036)
Malaria by affan ali(036)Malaria by affan ali(036)
Malaria by affan ali(036)
AFFAN ALI
 
HIV AND OPPORTUNISTIC INFECTIONS IN HIV.pptx
HIV AND OPPORTUNISTIC INFECTIONS  IN HIV.pptxHIV AND OPPORTUNISTIC INFECTIONS  IN HIV.pptx
HIV AND OPPORTUNISTIC INFECTIONS IN HIV.pptx
drsriram2001
 
Acyclovir
AcyclovirAcyclovir
Acyclovir
Aya Ali
 
Uti a surgeons perspective
Uti a surgeons perspectiveUti a surgeons perspective
Uti a surgeons perspective
PRANAYA PANIGRAHI
 
Pelvic inflammatory disease
Pelvic inflammatory diseasePelvic inflammatory disease
Pelvic inflammatory disease
Tevfik Yoldemir
 
Vaginal disgarge
Vaginal disgargeVaginal disgarge
Vaginal disgarge
tariggally
 

Similar to sexually transmitted diseases (20)

2015 guia de cdc para tto de ets y vb
2015 guia de cdc para tto de ets y vb2015 guia de cdc para tto de ets y vb
2015 guia de cdc para tto de ets y vb
 
Gynecology genital disease and treatment Dr. Ahmadi.pdf
Gynecology genital disease and treatment Dr. Ahmadi.pdfGynecology genital disease and treatment Dr. Ahmadi.pdf
Gynecology genital disease and treatment Dr. Ahmadi.pdf
 
DOH National Antibiotic Guidelines 2016 (UTI)
DOH National Antibiotic Guidelines 2016 (UTI)DOH National Antibiotic Guidelines 2016 (UTI)
DOH National Antibiotic Guidelines 2016 (UTI)
 
Global Medical Cures™ | Sexually Transmitted Diseases (CDC Treatment Guidelines)
Global Medical Cures™ | Sexually Transmitted Diseases (CDC Treatment Guidelines)Global Medical Cures™ | Sexually Transmitted Diseases (CDC Treatment Guidelines)
Global Medical Cures™ | Sexually Transmitted Diseases (CDC Treatment Guidelines)
 
Chlamydia Infection
Chlamydia Infection Chlamydia Infection
Chlamydia Infection
 
Urinary Tract Infection-1.pptx
Urinary Tract Infection-1.pptxUrinary Tract Infection-1.pptx
Urinary Tract Infection-1.pptx
 
2015 pocket-guide
2015 pocket-guide2015 pocket-guide
2015 pocket-guide
 
Infections in pregnancy and the puerperium.pptx
Infections in pregnancy and the puerperium.pptxInfections in pregnancy and the puerperium.pptx
Infections in pregnancy and the puerperium.pptx
 
A B C of URINARY TRACT INFECTION, Dr. Sharda Jain Lifecare Centre
A B C of URINARY TRACT INFECTION, Dr. Sharda Jain Lifecare Centre A B C of URINARY TRACT INFECTION, Dr. Sharda Jain Lifecare Centre
A B C of URINARY TRACT INFECTION, Dr. Sharda Jain Lifecare Centre
 
SINGLE DOSE treatment of URINARY TRACT INFECTION in women, Dr Sharda jain , ...
SINGLE DOSE  treatment of URINARY TRACT INFECTION in women, Dr Sharda jain , ...SINGLE DOSE  treatment of URINARY TRACT INFECTION in women, Dr Sharda jain , ...
SINGLE DOSE treatment of URINARY TRACT INFECTION in women, Dr Sharda jain , ...
 
Std
StdStd
Std
 
Ciprofloxacin 500mg film coated tablets smpc- taj pharmaceuticals
Ciprofloxacin 500mg film coated tablets smpc- taj pharmaceuticalsCiprofloxacin 500mg film coated tablets smpc- taj pharmaceuticals
Ciprofloxacin 500mg film coated tablets smpc- taj pharmaceuticals
 
2_2019_02_23!1ehefguuthutyj0_34_21_PM.pptx
2_2019_02_23!1ehefguuthutyj0_34_21_PM.pptx2_2019_02_23!1ehefguuthutyj0_34_21_PM.pptx
2_2019_02_23!1ehefguuthutyj0_34_21_PM.pptx
 
Brucellosis
BrucellosisBrucellosis
Brucellosis
 
Malaria by affan ali(036)
Malaria by affan ali(036)Malaria by affan ali(036)
Malaria by affan ali(036)
 
HIV AND OPPORTUNISTIC INFECTIONS IN HIV.pptx
HIV AND OPPORTUNISTIC INFECTIONS  IN HIV.pptxHIV AND OPPORTUNISTIC INFECTIONS  IN HIV.pptx
HIV AND OPPORTUNISTIC INFECTIONS IN HIV.pptx
 
Acyclovir
AcyclovirAcyclovir
Acyclovir
 
Uti a surgeons perspective
Uti a surgeons perspectiveUti a surgeons perspective
Uti a surgeons perspective
 
Pelvic inflammatory disease
Pelvic inflammatory diseasePelvic inflammatory disease
Pelvic inflammatory disease
 
Vaginal disgarge
Vaginal disgargeVaginal disgarge
Vaginal disgarge
 

More from Tevfik Yoldemir

Health promotion for healthy aging
Health promotion for healthy agingHealth promotion for healthy aging
Health promotion for healthy aging
Tevfik Yoldemir
 
Management of menopausal symptoms for breast cancer survivors
Management of menopausal symptoms for breast cancer survivorsManagement of menopausal symptoms for breast cancer survivors
Management of menopausal symptoms for breast cancer survivors
Tevfik Yoldemir
 
Endometriosis and IVF outcomes
Endometriosis and IVF outcomesEndometriosis and IVF outcomes
Endometriosis and IVF outcomes
Tevfik Yoldemir
 
Pelvic anatomy in relation with pelvic organ prolapse
Pelvic anatomy in relation with pelvic organ prolapsePelvic anatomy in relation with pelvic organ prolapse
Pelvic anatomy in relation with pelvic organ prolapse
Tevfik Yoldemir
 
Fetal viral infections
Fetal viral infectionsFetal viral infections
Fetal viral infections
Tevfik Yoldemir
 
Energy modalities used in MIGS
Energy modalities used in MIGSEnergy modalities used in MIGS
Energy modalities used in MIGS
Tevfik Yoldemir
 
Diagnosis of Endometriosis
Diagnosis of EndometriosisDiagnosis of Endometriosis
Diagnosis of Endometriosis
Tevfik Yoldemir
 
Tissue specific estrogen complex
Tissue specific estrogen complexTissue specific estrogen complex
Tissue specific estrogen complex
Tevfik Yoldemir
 
Premature ovarian insufficiency
Premature ovarian insufficiencyPremature ovarian insufficiency
Premature ovarian insufficiency
Tevfik Yoldemir
 
Management of Menopausal symptoms
Management of Menopausal symptomsManagement of Menopausal symptoms
Management of Menopausal symptoms
Tevfik Yoldemir
 
Contraception
ContraceptionContraception
Contraception
Tevfik Yoldemir
 
Bleeding in early pregnancy
Bleeding in early pregnancyBleeding in early pregnancy
Bleeding in early pregnancy
Tevfik Yoldemir
 
Abnormal uterine bleeding
Abnormal uterine bleedingAbnormal uterine bleeding
Abnormal uterine bleeding
Tevfik Yoldemir
 
Chronic pelvic pain
Chronic pelvic painChronic pelvic pain
Chronic pelvic pain
Tevfik Yoldemir
 
Endometriosis after the age of 40 years
Endometriosis after the age of 40 yearsEndometriosis after the age of 40 years
Endometriosis after the age of 40 years
Tevfik Yoldemir
 
Fibroids & fertility
Fibroids & fertilityFibroids & fertility
Fibroids & fertility
Tevfik Yoldemir
 
Fertility options after age of 40 years
Fertility options after age of 40 yearsFertility options after age of 40 years
Fertility options after age of 40 years
Tevfik Yoldemir
 
Phytochemicals and fetal epigenome
Phytochemicals and fetal epigenomePhytochemicals and fetal epigenome
Phytochemicals and fetal epigenome
Tevfik Yoldemir
 
Management of Rectovaginal fistula
Management of Rectovaginal fistulaManagement of Rectovaginal fistula
Management of Rectovaginal fistula
Tevfik Yoldemir
 
Current management of overactive bladder
Current management of overactive bladderCurrent management of overactive bladder
Current management of overactive bladder
Tevfik Yoldemir
 

More from Tevfik Yoldemir (20)

Health promotion for healthy aging
Health promotion for healthy agingHealth promotion for healthy aging
Health promotion for healthy aging
 
Management of menopausal symptoms for breast cancer survivors
Management of menopausal symptoms for breast cancer survivorsManagement of menopausal symptoms for breast cancer survivors
Management of menopausal symptoms for breast cancer survivors
 
Endometriosis and IVF outcomes
Endometriosis and IVF outcomesEndometriosis and IVF outcomes
Endometriosis and IVF outcomes
 
Pelvic anatomy in relation with pelvic organ prolapse
Pelvic anatomy in relation with pelvic organ prolapsePelvic anatomy in relation with pelvic organ prolapse
Pelvic anatomy in relation with pelvic organ prolapse
 
Fetal viral infections
Fetal viral infectionsFetal viral infections
Fetal viral infections
 
Energy modalities used in MIGS
Energy modalities used in MIGSEnergy modalities used in MIGS
Energy modalities used in MIGS
 
Diagnosis of Endometriosis
Diagnosis of EndometriosisDiagnosis of Endometriosis
Diagnosis of Endometriosis
 
Tissue specific estrogen complex
Tissue specific estrogen complexTissue specific estrogen complex
Tissue specific estrogen complex
 
Premature ovarian insufficiency
Premature ovarian insufficiencyPremature ovarian insufficiency
Premature ovarian insufficiency
 
Management of Menopausal symptoms
Management of Menopausal symptomsManagement of Menopausal symptoms
Management of Menopausal symptoms
 
Contraception
ContraceptionContraception
Contraception
 
Bleeding in early pregnancy
Bleeding in early pregnancyBleeding in early pregnancy
Bleeding in early pregnancy
 
Abnormal uterine bleeding
Abnormal uterine bleedingAbnormal uterine bleeding
Abnormal uterine bleeding
 
Chronic pelvic pain
Chronic pelvic painChronic pelvic pain
Chronic pelvic pain
 
Endometriosis after the age of 40 years
Endometriosis after the age of 40 yearsEndometriosis after the age of 40 years
Endometriosis after the age of 40 years
 
Fibroids & fertility
Fibroids & fertilityFibroids & fertility
Fibroids & fertility
 
Fertility options after age of 40 years
Fertility options after age of 40 yearsFertility options after age of 40 years
Fertility options after age of 40 years
 
Phytochemicals and fetal epigenome
Phytochemicals and fetal epigenomePhytochemicals and fetal epigenome
Phytochemicals and fetal epigenome
 
Management of Rectovaginal fistula
Management of Rectovaginal fistulaManagement of Rectovaginal fistula
Management of Rectovaginal fistula
 
Current management of overactive bladder
Current management of overactive bladderCurrent management of overactive bladder
Current management of overactive bladder
 

Recently uploaded

Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
SwisschemDerma
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
70KRISHPATEL
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
MGM SCHOOL/COLLEGE OF NURSING
 
Management of Traumatic Splenic injury.pptx
Management of Traumatic Splenic injury.pptxManagement of Traumatic Splenic injury.pptx
Management of Traumatic Splenic injury.pptx
AkshaySarraf1
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
chandankumarsmartiso
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
chandankumarsmartiso
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 

Recently uploaded (20)

Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
THERAPEUTIC ANTISENSE MOLECULES .pptx
THERAPEUTIC ANTISENSE MOLECULES    .pptxTHERAPEUTIC ANTISENSE MOLECULES    .pptx
THERAPEUTIC ANTISENSE MOLECULES .pptx
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
 
Management of Traumatic Splenic injury.pptx
Management of Traumatic Splenic injury.pptxManagement of Traumatic Splenic injury.pptx
Management of Traumatic Splenic injury.pptx
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 

sexually transmitted diseases

  • 1. 20.06.2018 1 Sexually transmitted diseases Tevfik Yoldemir MD BSc MA www.yoldemir.com Chancroid • The combination of a painful genital ulcer and tender suppurative inguinal adenopathy suggests the diagnosis of chancroid 1) the patient has one or more painful genital ulcers; 2) the clinical presentation, appearance of genital ulcers and, if present, regional lymphadenopathy are typical for chancroid; 3) the patient has no evidence of T. pallidum infection by darkfield examination of ulcer exudate or by a serologic test for syphilis performed at least 7 days after onset of ulcers; and 4) an HSV PCR test or HSV culture performed on the ulcer exudate is negative Chancroid Recommended Regimens Azithromycin 1 g orally in a single dose OR Ceftriaxone 250 mg IM in a single dose OR Ciprofloxacin 500 mg orally twice a day for 3 days OR Erythromycin base 500 mg orally three times a day for 7 days Herpes • Painful multiple vesicular or ulcerative lesions typically associated with HSV are absent in many infected persons. • Cell culture and PCR are the preferred HSV tests for persons who seek medical treatment for genital ulcers or other mucocutaneous lesions. Recommended Regimens Acyclovir 400 mg orally three times a day for 7–10 days OR Acyclovir 200 mg orally five times a day for 7–10 days OR Valacyclovir 1 g orally twice a day for 7–10 days OR Famciclovir 250 mg orally three times a day for 7–10 days Suppressivetherapyfor recurrentgenital herpes Recommended Regimens Acyclovir 400 mg orally twice a day OR Valacyclovir 500 mg orally once a day* OR Valacyclovir 1 g orally once a day OR Famiciclovir 250 mg orally twice a day Episodictherapyforrecurrentgenital herpes Recommended Regimens Acyclovir 400 mg orally three times a day for 5 days OR Acyclovir 800 mg orally twice a day for 5 days OR Acyclovir 800 mg orally three times a day for 2 days OR Valacyclovir 500 mg orally twice a day for 3 days OR Valacyclovir 1 g orally once a day for 5 days OR Famciclovir 125 mg orally twice daily for 5 days OR Famciclovir 1 gram orally twice daily for 1 day OR Famciclovir 500 mg once, followed by 250 mg twice daily for 2 days
  • 2. 20.06.2018 2 Suppressivetherapyof a pregnantwomen Recommended regimenfor suppressive therapy of pregnant women with recurrent genital herpes * Acyclovir 400 mg orally three times a day OR Valacyclovir 500 mg orally twice a day * Treatment recommended starting at 36 weeks of gestation GranulomaInguinale(Donovanosis) • Painless, slowly progressive ulcerative lesions on the genitals or perineum without regional lymphadenopathy; subcutaneous granulomas (pseudobuboes) also might occur. • The lesions are highly vascular (i.e., beefy red appearance) and bleed. • Extragenitalinfection can occur with extension of infection to the pelvis, or it can disseminate to intra-abdominal organs, bones, or the mouth. • The lesions also can develop secondary bacterial infection and can coexist with other sexually transmitted pathogens. • Diagnosis requires visualization of dark-staining Donovan bodies on tissue crush preparation or biopsy. RecommendedRegimen Azithromycin 1 g orally once per week or 500 mg daily for at least 3 weeks and until all lesions have completely healed Alternative Regimens Doxycycline 100 mg orally twice a day for at least 3 weeks and until all lesions have completely healed OR Ciprofloxacin 750 mg orally twice a day for at least 3 weeks and until all lesions have completely healed OR Erythromycin base 500 mg orally four times a day for at least 3 weeks and until all lesions have completely healed OR Trimethoprim-sulfamethoxazole one double-strength (160 mg/800 mg) tablet orally twice a day for at least 3 weeks and until all lesions have completely healed LymphogranulomaVenereum • tender inguinal and/or femoral lymphadenopathy that is typicallyunilateral. • A self-limited genital ulcer or papule sometimes occurs at the site of inculation. • Genital lesions, rectal specimens, and lymph node specimens (i.e., lesion swab or bubo aspirate) can be tested for C. trachomatis by culture, direct immunofluorescence, or nucleic acid detection • Chlamydia serology (complement fixation titers ≥1:64 or microimmunofluorescencetiters >1:256) might support the diagnosis of LGV Recommended Regimen Doxycycline 100 mg orally twice a day for 21 days Alternative Regimen Erythromycin base 500 mg orally four times a day for 21 days Syphilis • Persons who have syphilis might seek treatment for signs or symptoms of primary syphilis infection (i.e., ulcers or chancre at the infection site), • secondary syphilis (i.e., manifestations that include, but are not limited to, skin rash, mucocutaneous lesions, and lymphadenopathy), or • tertiary syphilis (i.e., cardiac, gummatous lesions, tabes dorsalis, and general paresis). • Darkfield examinations and tests to detect T. pallidum directly from lesion exudate or tissue are the definitive methods for diagnosing early syphilis.
  • 3. 20.06.2018 3 Recommended Regimen for Adults* Benzathine penicillin G 2.4 million units IM in a single dose Recommended Regimens for Adults* Early Latent Syphilis Benzathine penicillin G 2.4 million units IM in a single dose Late Latent Syphilis or Latent Syphilis of Unknown Duration Benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1-week intervals Recommended Regimen for Infants and Children Benzathine penicillin G 50,000 units/kg IM, up to the adult dose of 2.4 million units in a single dose Recommended Regimens for Infants and Children Early Latent Syphilis Benzathine penicillin G 50,000 units/kg IM, up to the adult dose of 2.4 million units in a single dose Late Latent Syphilis Benzathine penicillin G 50,000 units/kg IM, up to the adult dose of 2.4 million units, administered as 3 doses at 1-week intervals (total 150,000 units/kg up to the adult total dose of 7.2 million units) ChlamydialInfections • C. trachomatis urogenital infection can be diagnosed in women by testing first-catch urine or collecting swab specimens from the endocervix or vagina. • Diagnosis of C. trachomatis urethral infection in men can be made by testing a urethral swab or first-catch urine specimen. Recommended Regimens Azithromycin 1 g orally in a single dose OR Doxycycline 100 mg orally twice a day for 7 days Alternative Regimens Erythromycin base 500 mg orally four times a day for 7 days OR Erythromycin ethylsuccinate 800 mg orally four times a day for 7 days OR Levofloxacin 500 mg orally once daily for 7 days OR Ofloxacin 300 mg orally twice a day for 7 days Pregnancy Recommended Regimens Azithromycin 1 g orally in a single dose Alternative Regimens Amoxicillin 500 mg orally three times a day for 7 days OR Erythromycin base 500 mg orally four times a day for 7 days OR Erythromycin base 250 mg orally four times a day for 14 days OR Erythromycin ethylsuccinate 800 mg orally four times a day for 7 days OR Erythromycin ethylsuccinate 400 mg orally four times a day for 14 days GonococcalInfections • Culture and NAAT are available for the detection of genitourinary infection with N. gonorrhoeae (394); culture requires endocervical (women) or urethral (men) swab specimens • Detection of infection using Gram stain of endocervical, pharyngeal, and rectal specimens also is insufficient and is not recommended. MB/GV stain of urethral secretions is an alternative point-of-care diagnostic test with performance characteristics similar to Gram stain. • Presumed gonococcal infection is established by documenting the presence of WBC containing intracellular purple diplococci in MB/GV smears.
  • 4. 20.06.2018 4 Recommended Regimen Ceftriaxone 250 mg IM in a single dose PLUS Azithromycin 1g orally in a single dose Alternative Regimens If ceftriaxone is not available: Cefixime 400 mg orally in a single dose PLUS Azithromycin 1 g orally in a single dose BacterialVaginosis • anaerobic bacteria (e.g., Prevotella sp. and Mobiluncus sp.), G. vaginalis, Ureaplasma, Mycoplasma, and numerous fastidious or uncultivated anaerobes. • Gram stain (considered the gold standard laboratory method for diagnosing BV) is used to determine the relative concentration of lactobacilli (i.e., long Gram-positive rods), Gram-negative and Gram-variable rods and cocci (i.e., G. vaginalis, Prevotella, Porphyromonas, and peptostreptococci), and curved Gram-negative rods (i.e., Mobiluncus) characteristic of BV. Clinical criteria require three of the following symptoms or signs: • homogeneous, thin, white discharge that smoothly coats the vaginal walls; • clue cells (e.g., vaginal epithelial cells studded with adherent coccoobacilli) on microscopic examination; • pH of vaginal fluid >4.5; or • a fishy odor of vaginal discharge before or after addition of 10% KOH (i.e., the whiff test). RecommendedRegimens Metronidazole 500 mg orally twice a day for 7 days OR Metronidazole gel 0.75%, one full applicator (5 g) intravaginally, once a day for 5 days OR Clindamycin cream 2%, one full applicator (5 g) intravaginally at bedtime for 7 days Alternative Regimens Tinidazole 2 g orally once daily for 2 days OR Tinidazole 1 g orally once daily for 5 days OR Clindamycin 300 mg orally twice daily for 7 days OR Clindamycin ovules 100 mg intravaginally once at bedtime for 3 days* Trichomoniasis Recommended Regimen Metronidazole 2 g orally in a single dose OR Tinidazole 2 g orally in a single dose Alternative Regimen Metronidazole 500 mg orally twice a day for 7 days VulvovaginalCandidiasis • Use of 10% KOH in wet preparations improves the visualization of yeast and mycelia by disrupting cellular material that might obscure the yeast or pseudohyphae. • Examination of a wet mount with KOH preparation should be performed for all women with symptoms or signs of VVC
  • 5. 20.06.2018 5 VulvovaginalCandidiasis Recommended Regimens Over-the-Counter Intravaginal Agents: Clotrimazole 1% cream 5 g intravaginally daily for 7–14 days OR Clotrimazole 2% cream 5 g intravaginally daily for 3 days OR Miconazole 2% cream 5 g intravaginally daily for 7 days OR Miconazole 4% cream 5 g intravaginally daily for 3 days OR Miconazole 100 mg vaginal suppository, one suppository daily for 7 da OR Miconazole 200 mg vaginal suppository, one suppository for 3 days OR Miconazole 1,200 mg vaginal suppository, one suppository for 1 day OR Tioconazole 6.5% ointment 5 g intravaginally in a single application • Prescription Intravaginal Agents: • Butoconazole 2% cream (single dose bioadhesive product), 5 g intravaginally in a single application • OR • Terconazole 0.4% cream 5 g intravaginally daily for 7 days • OR • Terconazole 0.8% cream 5 g intravaginally daily for 3 days • OR • Terconazole 80 mg vaginal suppository, one suppository daily for 3 days • Oral Agent: • Fluconazole 150 mg orally in a single dose Pelvic InflammatoryDisease If one or more of the following minimum clinical criteria are present on pelvic examination: • cervical motion tenderness or uterine tenderness or adnexal tenderness. One or more of the following additional criteria can be used to enhance the specificity of the minimum clinical criteria and support a diagnosis of PID: • oral temperature >101°F (>38.3°C); • abnormal cervical mucopurulent discharge or cervical friability; • presence of abundant numbers of WBC on saline microscopy of vaginal fluid; • elevated erythrocyte sedimentation rate; • elevated C-reactive protein; and • laboratory documentation of cervical infection with N. gonorrhoeae or C. trachomatis. DifferentialDiagnosisfor PID • Endometriosis • Appendicitis & other gastro conditions • Appendicitis is unilateral and right sided • PID is bilateral • Ectopic pregnancy • Always do a pregnancy test • Urinary tract infection or stone • “Ovarian cysts” • Lower genital tract infection PID Sequelae • Chronic Pelvic Pain (15-20 %) • Ectopic pregnancy (6-10 fold ↑Risk) • At least 50% of tubal pregnancies have histology of PID • Infertility (Tubal) • 10 – 15% after one episode • 20% ~ 2 episode • >40% ~ 3 episodes • Recurrence of acute PID at least 25% • Male genital disease in 25%
  • 6. 20.06.2018 6 RecommendedParenteralRegimens Cefotetan 2 g IV every 12 hours PLUS Doxycycline 100 mg orally or IV every 12 hours OR Cefoxitin 2 g IV every 6 hours PLUS Doxycycline 100 mg orally or IV every 12 hours OR Clindamycin 900 mg IV every 8 hours PLUS Gentamicin loading dose IV or IM (2 mg/kg), followed by a maintenance dose (1.5 mg/kg) every 8 hours. Single daily dosing (3–5 mg/kg) can be substituted. AlternativeParenteralRegimen Ampicillin/Sulbactam 3 g IV every 6 hours PLUS Doxycycline 100 mg orally or IV every 12 hours RecommendedIntramuscular/OralRegimens Ceftriaxone 250 mg IM in a single dose PLUS Doxycycline 100 mg orally twice a day for 14 days WITH* or WITHOUT Metronidazole 500 mg orally twice a day for 14 days OR Cefoxitin 2 g IM in a single dose and Probenecid, 1 g orally administered concurrently in a single dose PLUS Doxycycline 100 mg orally twice a day for 14 days WITH or WITHOUT Metronidazole 500 mg orally twice a day for 14 days OR Other parenteral third-generation cephalosporin (e.g., ceftizoxime or cefotaxime) PLUS Doxycycline 100 mg orally twice a day for 14 days WITH* or WITHOUT Metronidazole 500 mg orally twice a day for 14 days RecommendedRegimensfor External AnogenitalWarts (i.e., penis, groin, scrotum, vulva, perineum, external anus, and perianus*) Patient-Applied: Imiquimod 3.75% or 5% cream† OR Podofilox 0.5% solution or gel OR Sinecatechins 15% ointment† Provider–Administered: Cryotherapy with liquid nitrogen or cryoprobe OR Surgical removal either by tangential scissor excision, tangential shave excision, curettage, laser, or electrosurgery OR Trichloroacetic acid (TCA) or bichloroacetic acid (BCA) 80%–90% solution RecommendedRegimensfor Vaginal Warts Cryotherapy with liquid nitrogen. The use of a cryoprobe in the vagina is not recommended because of the risk for vaginal perforation and fistula formation. OR Surgical removal OR TCA or BCA 80%–90% solution RecommendedRegimensfor CervicalWarts Cryotherapy with liquid nitrogen OR Surgical removal OR TCA or BCA 80%–90% solution Management of cervical warts should include consultation with a specialist. For women who have exophytic cervical warts, a biopsy evaluation to exclude high-grade SIL must be performed before treatment is initiated